tbuckley/cabot-search huggingface dataset:
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis
Authors: Sebastian Bickelhaupt, Christian Erbel, Carmen Timke, Ute Wirkner, Monika Dadrich, Paul Flechsig, Alexandra Tietz, Johanna Pföhler, Wolfgang Gross, Peter Peschke, Line Hoeltgen, Hugo A. Katus, Hermann-Josef Gröne, Nils H. Nicolay, Rainer Saffrich, Jürgen Debus, Mark D. Sternlicht, Todd W. Seeley, Kenneth E. Lipson, Peter E. Huber
Journal: JNCI Journal of the National Cancer Institute (2016)

Radiotherapy is a mainstay for the treatment of lung cancer that can induce pneumonitis or pulmonary fibrosis. The matricellular protein connective tissue growth factor (CTGF) is a central mediator of tissue remodeling. A radiation-induced mouse model of pulmonary fibrosis was used to determine if transient administration of a human antibody to CTGF (FG-3019) started at different times before or after 20 Gy thoracic irradiation reduced acute and chronic radiation toxicity. Mice (25 mice/group; 10 mice/group in a confirmation study) were examined by computed tomography, histology, gene expression changes, and for survival. In vitro experiments were performed to directly study the interaction of CTGF blockade and radiation. All statistical tests were two-sided. Administration of FG-3019 prevented (∼50%-80%) or reversed (∼50%) lung remodeling, improved lung function, improved mouse health, and rescued mice from lethal irradiation ( P < .01). Importantly, when antibody treatment was initiated at 16 weeks after thoracic irradiation, FG-3019 reversed established lung remodeling and restored lung function. CTGF blockade abrogated M2 polarized macrophage influx, normalized radiation-induced gene expression changes, and reduced myofibroblast abundance and Osteopontin expression. These results indicate that blocking CTGF attenuates radiation-induced pulmonary remodeling and can reverse the process after initiation. CTGF has a central role in radiation-induced fibrogenesis, and FG-3019 may benefit patients with radiation-induced pulmonary fibrosis or patients with other forms or origin of chronic fibrotic diseases.
Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients
Authors: Athina Fonia, Carlo Cota, Jane F. Setterfield, Lynne J. Goldberg, David A. Fenton, Catherine M. Stefanato
Journal: Journal of the American Academy of Dermatology (2017)
Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder
Authors: Ryan K C Yuen, Daniele Merico, Matt Bookman, Jennifer L Howe, Bhooma Thiruvahindrapuram, Rohan V Patel, Joe Whitney, Nicole Deflaux, Jonathan Bingham, Zhuozhi Wang, Giovanna Pellecchia, Janet A Buchanan, Susan Walker, Christian R Marshall, Mohammed Uddin, Mehdi Zarrei, Eric Deneault, Lia D'Abate, Ada J S Chan, Stephanie Koyanagi, Tara Paton, Sergio L Pereira, Ny Hoang, Worrawat Engchuan, Edward J Higginbotham, Karen Ho, Sylvia Lamoureux, Weili Li, Jeffrey R MacDonald, Thomas Nalpathamkalam, Wilson W L Sung, Fiona J Tsoi, John Wei, Lizhen Xu, Anne-Marie Tasse, Emily Kirby, William Van Etten, Simon Twigger, Wendy Roberts, Irene Drmic, Sanne Jilderda, Bonnie MacKinnon Modi, Barbara Kellam, Michael Szego, Cheryl Cytrynbaum, Rosanna Weksberg, Lonnie Zwaigenbaum, Marc Woodbury-Smith, Jessica Brian, Lili Senman, Alana Iaboni, Krissy Doyle-Thomas, Ann Thompson, Christina Chrysler, Jonathan Leef, Tal Savion-Lemieux, Isabel M Smith, Xudong Liu, Rob Nicolson, Vicki Seifer, Angie Fedele, Edwin H Cook, Stephen Dager, Annette Estes, Louise Gallagher, Beth A Malow, Jeremy R Parr, Sarah J Spence, Jacob Vorstman, Brendan J Frey, James T Robinson, Lisa J Strug, Bridget A Fernandez, Mayada Elsabbagh, Melissa T Carter, Joachim Hallmayer, Bartha M Knoppers, Evdokia Anagnostou, Peter Szatmari, Robert H Ring, David Glazer, Mathew T Pletcher, Stephen W Scherer
Journal: Nature Neuroscience (2017)
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Authors: Anuradha Banerjee, Regina I. Jakacki, Arzu Onar-Thomas, Shengjie Wu, Theodore Nicolaides, Tina Young Poussaint, Jason Fangusaro, Joanna Phillips, Arie Perry, David Turner, Michael Prados, Roger J. Packer, Ibrahim Qaddoumi, Sridharan Gururangan, Ian F. Pollack, Stewart Goldman, Lawrence A. Doyle, Clinton F. Stewart, James M. Boyett, Larry E. Kun, Maryam Fouladi
Journal: Neuro-Oncology (2017)

Activation of the mitogen-activated protein kinase pathway is important for growth of pediatric low-grade gliomas (LGGs). The aim of this study was to determine the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumetinib in children with progressive LGG. Selumetinib was administered orally starting at 33 mg/m2/dose b.i.d., using the modified continual reassessment method. Pharmacokinetic analysis was performed during the first course. BRAF aberrations in tumor tissue were determined by real-time polymerase chain reaction and fluorescence in situ hybridization. Thirty-eight eligible subjects were enrolled. Dose levels 1 and 2 (33 and 43 mg/m2/dose b.i.d.) were excessively toxic. DLTs included grade 3 elevated amylase/lipase (n = 1), headache (n = 1), mucositis (n = 2), and grades 2–3 rash (n = 6). At dose level 0 (25 mg/m2/dose b.i.d, the RP2D), only 3 of 24 subjects experienced DLTs (elevated amylase/lipase, rash, and mucositis). At the R2PD, the median (range) area under the curve (AUC0-∞) and apparent oral clearance of selumetinib were 3855 ng*h/mL (1780 to 7250 ng × h/mL) and 6.5 L × h−1 × m−2 (3.4 to 14.0 L × h−1 × m−2), respectively. Thirteen of 19 tumors had BRAF abnormalities. Among the 5 (20%) of 25 subjects with sustained partial responses, all at the RP2D, 4 had BRAF aberrations, 1 had insufficient tissue. Subjects received a median of 13 cycles (range: 1–26). Fourteen (37%) completed all protocol treatment (26 cycles [n = 13], 13 cycles [n = 1]) with at least stable disease; 2-year progression-free survival at the RP2D was 69 ± SE 9.8%. Selumetinib has promising antitumor activity in children with LGG. Rash and mucositis were the most common DLTs.
Alternative Splicing of PDCD2 Regulates Hematopoietic Stem Cell Specification, and Drives Multilineage Leukemia Development.
Authors: Joseph J Kramer, Svetlana Minakhina, Neil Campbell, Stephani Marshall, Katherine Piso, Arnold B. Rabson, Ruth Steward, Dale Schaar, Hatem Sabaawy
Journal: Blood (2009)
The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in <i>KRAS</i>-wild-type colorectal cancer
Authors: De-Wei Wu, Po-Lin Lin, Lee Wang, Chi-Chou Huang, Huei Lee
Journal: Theranostics (2017)

The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, increased KRAS expression induced ROS production, which elevated HIF-1α and YAP1 expression. Increased HIF-1α persistently promoted DDX3 expression via a KRAS/ROS/HIF-1α feedback loop. DDX3-mediated aggressiveness and CTX resistance were regulated by the YAP1/SIX2 axis in KRAS-WT cells and further confirmed in animal models. Kaplan-Meier and Cox regression analysis indicated that DDX3, KRAS, and YAP1 expression had prognostic value for OS and RFS in KRAS-WT and KRAS-mutated tumors, but SIX2 and YAP1/SIX2 were prognostic value only in KRAS-WT patients. The observation from patients seemed to support the mechanistic action of cell and animal models. We therefore suggest that combining YAP1 inhibitors with CTX may therefore suppress DDX3-mediated tumor aggressiveness and enhance CTX sensitivity in KRAS-WT colorectal cancer.
Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia
Authors: Anish Puliyayil Nair, Patricia A. Walker, Anna Kalff, Krystal Bergin, Sharon Avery, David J. Curtis, Sushrut S. Patil, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, Andrew Spencer
Journal: Blood (2015)
Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries
Authors: Francesco Blasi, Alberto Matteelli, Giovanni Sotgiu, Daniela Maria Cirillo, Fabrizio Palmieri, Lanfranco Fattorini, Giovanni Battista Migliori
Journal: European Respiratory Journal (2017)

In 2014 the World Health Assembly endorsed the new End Tuberculosis Strategy that aims at reducing the global incidence of the disease by 90% within 2035 [1]. Consensus document to advocate and ensure proper implementation of WHO recommendations on TB elimination in Italy <http://ow.ly/BHJC307S2U4>
Sixty seconds on . . . skunk
Authors: Anne Gulland
Journal: BMJ (2017)

You’re such a square. It’s a form of high potency cannabis, and researchers from the Institute of Psychiatry, Psychology and Neuroscience at King’s College and University College London are warning of its harms.1

Despite cannabis use falling in the UK, particularly among young people, rates of treatment for addiction are increasing. Most cannabis users in the UK use skunk rather than …
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production
Authors: Jing Du, Katelyn Paz, Ryan Flynn, Ante Vulic, Tara M. Robinson, Katie E. Lineburg, Kylie A. Alexander, Jingjing Meng, Sabita Roy, Angela Panoskaltsis-Mortari, Michael Loschi, Geoffrey R. Hill, Jonathan S. Serody, Ivan Maillard, David Miklos, John Koreth, Corey S. Cutler, Joseph H. Antin, Jerome Ritz, Kelli P. MacDonald, Timothy W. Schacker, Leo Luznik, Bruce R. Blazar
Journal: Blood (2017)
Efficacy of Rituximab in Hairy Cell Leukemia.
Authors: Styliani I. Kokoris, Maria K. Angelopoulou, Zacharoula I. Galani, Konstantinos Anargyrou, Sotirios Sachanas, Theodoros P. Vassilakopoulos, Marina P. Siakantaris, Flora N. Kontopidou, Evangelia M. Dimitriadou, Maria N. Dimopoulou, Panayiotis Tsaftaridis, Eleni Plata, Christina Kalpadakis, Marie-Christine Kyrtsonis, Panayiotis Panayiotidis, Gerassimos A. Pangalis
Journal: Blood (2006)
Investigation of Two Combination HbF Induction Regimens, RN-1 and Hydroxyurea Versus RN-1 and Decitabine, in a Humanized Sickle Cell Mouse Model
Authors: Ramasamy Jagadeeswaran, Yash Agarwal, Vinzon Ibanez, Maria Armila Ruiz, Kestis Vaitkus, Joseph DeSimone, Donald Lavelle, Angela Rivers
Journal: Blood (2015)
Anti-HTLV-I Tax-Protein-Specific CTL Is Not Necessarily Resposible for Graft-v.s.-ATL Effect in Allogeneic SCT for Patients with Adult T-Cell Leukemia/Lymphoma.
Authors: Hiroshi Fujiwara, Izumi Masamoto, Tomohiro Kozako, Hideaki Kawada, Makoto Yoshimitsu, Noriko Aoki, Atsuo Ozaki, Heiichiro Hamada, Kakushi Matsushita, Naomichi Arima, Chuwa Tei
Journal: Blood (2005)
Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy
Authors: Praful Ravi, Shaji Kumar, Wilson I Gonsalves, Francis K Buadi, Martha Q. Lacy, Ronald S. Go, Angela Dispenzieri, Prashant Kapoor, John A Lust, David Dingli, Yi Lin, Stephen J. Russell, Nelson Leung, Morie A. Gertz, Robert A. Kyle, Leif Bergsagel, S. Vincent Rajkumar
Journal: Blood (2016)
Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study of 40,011 Patients
Authors: Natalie Ertz-Archambault, Gretchen Taylor, Heidi E. Kosiorek, Amylou Constance Dueck, Janna Castro, Rob Marino, Susanne Gauthier, Katalin Kelemen, Laura E. Finn, Lisa Sproat, Jeanne Palmer, Ruben Mesa, Aref Al-Kali, James M. Foran, Raoul Tibes
Journal: Blood (2016)
Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Authors: Guillermo Garcia-Manero, Francesco Paolo Tambaro, Nebiyou Bekele, Hui Yang, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, Stefan Faderl, Jorge E. Cortes, Mark Brandt, Yumin Hu, Deborah McCue, Willie Mae Newsome, Sherry Pierce, Marcos DeLima, Hagop M. Kantarjian
Journal: Blood (2011)
Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia
Authors: Stephen T. Oh, Christopher A. Miller, Yevgeniy Gindin, Taylor M. Brost, Jason Chan, Mary C. Fulbright, Daniel A.C. Fisher, Eric J. Duncavage, Michelle O'Laughlin, Malachi Griffith, Obi L. Griffith, Lukas D. Wartman
Journal: Blood (2016)
Quality of life (QoL) and content validity in objective tumor response.
Authors: Christopher Twelves, Ahmad Awada, Peter Andrew Kaufman, Louise Yelle, Edith A. Perez, Galina Velikova, Jantien Wanders, Martin S. Olivo, Yi He, Corina Dutcus, W. Robert Simons, Javier Cortes
Journal: Journal of Clinical Oncology (2013)

1055^ Background: Key properties of QoL instruments in a clinical trial setting are reliability, the ability to detect a change, and content validity. Using data from the Study 301 phase III breast cancer trial, we report here content validity and ability to detect a change for the EORTC QLQ-C30 and breast cancer-specific QLQ-BR23 questionnaires. Methods: Patients with locally advanced or metastatic breast cancer were randomized to 21-day cycles of either eribulin mesylate 1.4 mg/m 2 given on Days 1 and 8, or capecitabine 1.25 g/m 2 BID orally on Days 1-14. QoL questionnaires were completed at baseline and at 6 weeks, 3, 6, 12, 18, and 24 months. Objective tumor response was evaluated (complete response [CR]; partial response [PR]; stable disease [SD]; progressive disease [PD]). Univariate and multivariate longitudinal analyses using weighted generalized estimating equations were employed to assess the responsiveness of the QoL scales to objective tumor response. Results: 1,102 patients were randomized (554 eribulin, 548 capecitabine). Global health status (GHS)/QoL scores were low at baseline (55). GHS/QoL scores were highest for patients with CR (70.8), followed by those patients with PR (63.5), SD (60.5), and PD (58.1). Physical functioning followed the same pattern: CR (98.3); PR (79.1); SD (72.8); PD (71.0). Role and social functioning scores were also responsive. Pain increased, while fatigue and body image worsened, with poorer tumor responses. Using the weighted generalized estimating equations, there were improvements in physical (34.78; p&lt;0.01), cognitive (27.29; p&lt;0.01), and social (22.04; p&lt;0.01) functioning, and future perspective 11.47 (p&lt;0.01), in patients who responded (CR and PR) to treatment compared with non-responders. Pain decreased significantly by 28.62 (p&lt;0.01) on a 0-100 scale. Patients who responded also gained appetite and had fewer breast symptoms. Conclusions: These results suggest content validity of the EORTC QLQ-30 and QLQ-BR23 questionnaires as they correlate with changes in objective tumor assessments. Clinical trial information: NCT00337103.
Drug Efflux Transporters and Imatinib Mesylate Insensitivity in Chronic Myeloid Leukemia
Authors: Caroline Fátima Aquino Moreira-Nunes, Ana Cristina Simões Beltrão, Larissa Tatiana Valente Martins Francês, Rodrigo Guarischi Mattos Amaral Sousa, Israel Tojal Silva, Artur Luiz Silva, Wilson Araújo Silva-Jr, José Alexandre Rodrigues Lemos
Journal: Blood (2012)
Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1)
Authors: Melisa Martinez- Paniagua, Mario I. Vega, Sara Huerta-Yepez, Bonilla Gonzalez, Vanessa Suarez, Stavroula Baritaki, James R. Berenson, Benjamin Bonavida
Journal: Blood (2008)
A Prospective Randomised Trial of Intravenous Iron Therapy Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Australian Women
Authors: Alhossain A. Khalafallah, Amanda Dennis, Joan Bates, Gerald Bates, Lauern Smith, Susie Shaw, David Seaton, John Berteram, Iain Robertson, Madeleine Ball, Michael Beamish, Kim Rooney, Terry Brain
Journal: Blood (2007)
In left main CAD, PCI with everolimus-eluting stents was noninferior to CABG for death, MI, or stroke at 3 years
Authors: Eric R. Bates
Journal: Annals of Internal Medicine (2017)

Source Citation Stone GW, Sabik JF, Serruys PW, et al; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016;375:2223-35. 27797291
Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma
Authors: Loredana Santo, Teru Hideshima, Andrew L. Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, John H. van Duzer, Ralph Mazitschek, Diana Cirstea, Homare Eda, Tyler A. Scullen, Scott Rodig, Miriam Canavese, James Bradner, Kenneth C Anderson, Simon Jones, Noopur S. Raje
Journal: Blood (2011)
A Specialty Clinic for Functional Gastrointestinal Disorders in Tertiary Care: Concept and Patient Population
Authors: Sabrina Berens, Felicitas Kraus, Annika Gauss, Jonas Tesarz, Wolfgang Herzog, Beate Niesler, Esther Stroe-Kunold, Rainer Schaefert
Journal: Clinical Gastroenterology and Hepatology (2017)
Should We Hold the Point of allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Haemoglobinuria in Eculizumab Era?
Authors: Feng Chen, Wu Depei, Aining Sun, XiaoWen Tang, Chengcheng Fu, Xiao Ma, Shengli Xue, Zhengming Jin
Journal: Blood (2014)
Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.
Authors: John Ben Liao, Ron E. Swensen, Jessica Reichow, Kelsie J Ovenell, Jennifer Childs, Doreen Higgins, Barbara Buening, Barbara Ann Goff, Chihiro Morishima, Mary L. Disis
Journal: Journal of Clinical Oncology (2015)

5580 Background: Antitumor immune responses in ovarian cancer have been associated with prolonged survival. In addition to direct cytotoxic activity, chemotherapies can also possess immunomodulatory properties. Paclitaxel may enhance metastasis and drug resistance by signaling via the TLR4 pathway. GM-CSF has been shown to induce the generation of myeloid dendritic cells and enhance antigen presentation. We hypothesized that weekly nab-paclitaxel followed by GM-CSF may enhance overall anti-tumor immunity. Methods: Peripheral blood mononuclear cells (PBMC) were evaluated by flow cytometry for circulating monocytes, dendritic cells, natural killer cells, T-lymphocytes, and myeloid derived suppressor cells (MDSC). Elispot assays for interferon gamma were performed on PBMC to identify immunity against ovarian cancer antigens. Results: Twenty-one patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer enrolled after receiving an average of 3 prior lines of chemotherapy. 52% had previously received bevacizumab. Median OS was 16.8 months. Mean time to progression was 5.5 months for those patients who achieved a CR and 4.5 months for those who did not. Overall response rate was 71% (29% CR, 43% PR). Interferon gamma Elispot responses at mean follow-up timepoints against insulin-like growth factor 1 receptor (IGF1R) correlated with time to progression (r = 0.723, p = 0.0035). The fold change achieved above baseline Elispot responses against IGF1R (r = 0.827, p = 0.0003) also correlated with time to progression. Levels of MDSC at time of study enrollment were associated with achieving a complete response to treatment (p = 0.0544). Conclusions: Our results show activity of this regimen and immune correlates for response have been identified. Rational combinations of immune modulators with cytotoxic chemotherapies should be investigated further for platinum resistant recurrent ovarian cancer with a focus on identifying immunologic synergies and those patients most likely to respond through immune biomarkers. Clinical trial information: NCT00466960.
Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.
Authors: Jeeyun Lee, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Seung Tae Kim, Kyoung-Mee Kim, Won Ki Kang
Journal: Journal of Clinical Oncology (2014)

4008 Background: The adjuvant chemoradiation therapy in stomach cancer (ARTIST) trial is the first study to investigate the efficacy of postoperative chemoradiation therapy as adjuvant treatment in gastric cancer patients with curative resection and extended D2 lymph node dissection. In this study, we report on the final analysis of the disease free survival (DFS) and survival (OS). Methods: XP arm received six cycles of XP (capecitabine 2000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks) chemotherapy. XP/XRT/XP arm received two cycles of XP followed by 45 Gy radiotherapy (capecitabine 1650 mg/m2/d for 5 weeks) and two cycles of XP. Preplanned subgroup analyses on Lauren classification and lymph node status were performed. EGFR, HER2 and MET overexpression were studied in this patient cohort and correaltive analyses with DFS and OS were performed. Results: Of 458 patients, 228 patients were randomized to the XP arm and 230 patients were randomized to the XP/XRT/XP arm. At final analysis, the addition of radiotherapy to XP chemotherapy did not significantly prolong DFS (HR 1.352, 95% CI 0.952 - 1.922; P=0.0922). In the intestinal subtype, however, DFS on the XP/XRT/XP arm was significantly prolonged when compared with XP alone (HR 2.883, 95% CI, 1.36 - 6.111, P=0.0057). In contrast, the addition of RT to XP in diffuse type GC did not considerably prolong DFS (HR 1.161, 95% CI, 0.753-1.791; P=0.4985). In accordance with the results from the first report, the DFS was superior in XP/XRT/XP then XP alone in LN(+) group. Currently, biomarker analyses including HER1, HER2, MET are being carried out. The correlative analyses between these markers and DFS/OS will be presented. Conclusions: Overall, the ARTIST trial was a negative trial with no significant difference in DFS between XP alone and XP/XRT/XP. However, XP/XRT/XP significantly prolonged DFS in intestinal type by Lauren classification when compared to XP alone. After a longer follow up duration, XP/XRT/XP seemed to benefit LN(+) GC patients. Hence, a subsequent ARTIST-II (TS-1 alone, TS-1/oxaliplatin, TS-1/oxaliplatin/RT) is enrolling patients with pathologic LN(+) GC. Clinical trial information: 00323830.